鎌状赤血球貧血検査・スクリーニング市場：技術、年齢層、セクター別-2025-2030年の世界予測

鎌状赤血球貧血検査・スクリーニング市場は、2023年に9億4,395万米ドルと評価され、2024年には10億7,069万米ドルに達すると予測され、CAGR 13.51％で成長し、2030年には22億9,322万米ドルに達すると予測されています。

鎌状赤血球貧血の検査とスクリーニングには、主にヘモグロビン電気泳動、高速液体クロマトグラフィー（HPLC）、遺伝子検査などの血液検査を通じて、鎌状赤血球症（SCD）と鎌状赤血球形質（SCT）を特定することを目的としたさまざまな診断技術が含まれます。これらの検査の必要性は、疼痛クライシス、脳卒中、臓器障害などの重篤な合併症を予防するための早期診断の必要性によって強調されており、その結果、患者の転帰と生活の質が改善されます。用途は、出生前スクリーニングから新生児検査、キャリア検査、リスクのある個人の日常的モニタリングにまで及ぶ。最終用途の範囲には、正確で迅速な診断能力を必要とするヘルスケア施設、調査機関、診断研究所が含まれます。

市場成長は、遺伝性疾患に対する認識の高まり、新生児スクリーニングプログラムに対する政府の取り組み、遺伝子検査における技術進歩などの要因に影響されます。アジア太平洋とアフリカの新興市場は、高い有病率とヘルスケアインフラ投資の増加により、大きなビジネスチャンスをもたらしています。企業に対する調査としては、パートナーシップによる地理的プレゼンスの拡大、非侵襲的検査法の研究への投資、認知度向上のためのアウトリーチプログラムの強化などが挙げられます。

しかし、低所得地域におけるヘルスケア施設へのアクセス制限、高度診断技術のコスト高、訓練された専門家の不足といった課題に直面しています。規制上のハードルも、新しい検査法の迅速なイントロダクションの妨げとなる可能性があります。これらを克服するために、革新的な分野としては、費用対効果が高く、携帯可能な検査ソリューションの開発や、遠隔地の人々にサービスを提供するための遠隔医療サービスの改善などが挙げられます。

研究の方向性としては、遺伝子診断や分子診断に焦点を当て、CRISPR技術を決定的な検査に応用することも考えられます。規制状況や患者のニーズの変化に適応するためには、継続的な市場分析が不可欠です。急速な技術革新と地域によって異なるヘルスケア能力を特徴とするこの市場では、成長機会を活用しながらこれらの課題に対処するための機敏な事業戦略が求められます。このようなダイナミックな環境では、企業は教育キャンペーン、利害関係者の協力、適応性のある製品開発に投資する必要があります。

市場力学：急速に進化する鎌状赤血球貧血検査・スクリーニング市場の主要市場インサイトを公開

鎌状赤血球貧血検査・スクリーニング市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の鎌状赤血球症の流行
  • 診断を支援するための継続的な政府の取り組み
  • 鎌状赤血球に対する高速液体クロマトグラフィー（HPLC）検査の大きな利用
• 市場抑制要因
  • 鎌状赤血球貧血に関連する診断と治療の問題
• 市場機会
  • 鎌状赤血球貧血の自動スクリーニングを実行するように設計されたディープラーニングフレームワークの開発
  • 非侵襲性、ハンドヘルド、デジタル技術の開発への注目の高まり
• 市場の課題
  • SCDに関連する臨床的不均一性と合併症
  • リソースの不足と熟練した臨床検査技師の不足

ポーターの5つの力鎌状赤血球貧血検査・スクリーニング市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：鎌状赤血球貧血検査・スクリーニング市場における外部からの影響の把握

外部マクロ環境要因は、鎌状赤血球貧血検査・スクリーニング市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析鎌状赤血球貧血検査・スクリーニング市場における競合情勢の把握

鎌状赤血球貧血検査・スクリーニング市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス鎌状赤血球貧血検査・スクリーニング市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、鎌状赤血球貧血検査・スクリーニング市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 鎌状赤血球症の世界の蔓延
    • 診断を支援するための政府の継続的な取り組み
    • 鎌状赤血球症に対する高速液体クロマトグラフィー（HPLC）検査の重要な利用
  • 抑制要因
    • 鎌状赤血球貧血症に関連する診断と治療の問題
  • 機会
    • 鎌状赤血球貧血症の自動スクリーニングを実行するために設計されたディープラーニングフレームワークの開発
    • 非侵襲性、携帯性、デジタル技術の開発への注目が高まる
  • 課題
    • SCDに関連する臨床的異質性と合併症
    • リソース不足と熟練した臨床検査技師の不足
• 市場セグメンテーション分析
  • 技術：特に新生児の初期スクリーニングのためのヘモグロビン電気泳動の継続的な進歩
  • セクター：企業ラボは、包括的なサービスを提供するために革新と技術の最前線に立っています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 鎌状赤血球貧血検査・スクリーニング市場：技術別

• ヘモグロビン電気泳動
  • 等電点電気泳動
• 高速液体クロマトグラフィー（HPLC）
• ポイントオブケア検査
  • ラテラルフロー免疫測定法
  • 紙ベースの迅速診断

第7章 鎌状赤血球貧血検査・スクリーニング市場：年齢層別

• 成人スクリーニング
• 新生児スクリーニング
• 1年目から25年目

第8章 鎌状赤血球貧血検査・スクリーニング市場セクター別

• コーポレートラボ
• 政府研究所
• プライベートラボ
• 官民パートナーシップ

第9章 南北アメリカの鎌状赤血球貧血検査・スクリーニング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の鎌状赤血球貧血検査・スクリーニング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの鎌状赤血球貧血検査・スクリーニング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 血圧薬のSCDへの転用研究に300万米ドルが授与される
  • Mylabが独自のポイントオブケア型迅速鎌状赤血球貧血検査を導入
  • ロードズ・マーク・インダストリーズとインド工科大学ボンベイ校が提携し、インドで鎌状赤血球検査を推進

企業一覧

• Biomedomics Inc.
• HiMedia Laboratories
• Pfizer Inc.
• Silver Lake Research Corporation
• Thermo Fisher Scientific Inc.
• Vertex Pharmaceuticals Incorporated
• Edvotek Inc.
• Atlas Medical GmbH
• Hemex Health
• Quest Diagnostics Incorporated
• CRISPR Therapeutics AG
• Anamol Laboratories Pvt. Ltd.
• Ulta Lab Tests, LLC
• Bio-Rad Laboratories, Inc.
• Bio Lab Diagnostics（I）Private Limited
• PerkinElmer, Inc.
• Bluebird bio, Inc.
• Streck, Inc.
• Maternova Inc.
• Laboratory Corporation of America Holdings
• Calibre Scientific, Inc.
• PicnicHealth
• Agios Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET RESEARCH PROCESS
• FIGURE 2. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SICKLE CELL ANEMIA TESTING & SCREENING MARKET DYNAMICS
• TABLE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ISOELECTRIC FOCUSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PAPER BASED RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ADULT SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY YEARS 1 TO 25, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CORPORATE LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC-PRIVATE-PARTNERSHIPS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 41. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 43. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 44. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 45. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 68. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 70. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 71. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 72. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 73. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 75. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 76. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 77. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 159. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 161. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 162. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 163. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 179. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 181. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 182. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 183. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 184. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 186. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 187. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 188. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
• TABLE 234. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 235. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

The Sickle Cell Anemia Testing & Screening Market was valued at USD 943.95 million in 2023, expected to reach USD 1,070.69 million in 2024, and is projected to grow at a CAGR of 13.51%, to USD 2,293.22 million by 2030.

Sickle Cell Anemia Testing and Screening encompasses a range of diagnostic techniques aimed at identifying sickle cell disease (SCD) and sickle cell trait (SCT), primarily through blood tests such as hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), and genetic testing. The necessity of these tests is underscored by the need for early diagnosis to prevent severe complications like pain crises, stroke, and organ damage, thus improving patient outcomes and quality of life. Applications extend from prenatal screening to newborn and carrier testing and routine monitoring for individuals at risk. The end-use scope includes healthcare facilities, research institutions, and diagnostic laboratories that require precise and rapid diagnostic capabilities.

Market growth is influenced by factors such as increased awareness of genetic disorders, government initiatives for newborn screening programs, and technological advancements in genetic testing. Emerging markets in Asia-Pacific and Africa present substantial opportunities due to high prevalence rates and increasing healthcare infrastructure investments. Recommendations for businesses include expanding geographic presence through partnerships, investing in research for non-invasive testing methods, and enhancing outreach programs to raise awareness.

However, market growth faces challenges such as limited access to healthcare facilities in low-income regions, high costs of advanced diagnostic technologies, and lack of trained professionals. Regulatory hurdles can also impede the swift introduction of new testing methods. To overcome these, innovation areas include developing cost-effective, portable testing solutions and improving telehealth services to reach remote populations.

Research directions could focus on genetic and molecular diagnostics, exploring CRISPR technology for definitive tests. Continuous market analytics is crucial to adapt to changing regulatory landscapes and patient needs. The market, characterized by rapid technological change and varying regional healthcare capabilities, requires agile business strategies to address these challenges while capitalizing on growth opportunities. This dynamic environment calls for companies to invest in education campaigns, stakeholder collaborations, and adaptive product development.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sickle Cell Anemia Testing & Screening Market

The Sickle Cell Anemia Testing & Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of Sickle Cell Disease Worldwide
  • Ongoing Government Initiatives to Support the Diagnosis
  • Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
• Market Restraints
  • Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
• Market Opportunities
  • Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
  • Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
• Market Challenges
  • Clinical Heterogeneity and Complications Associated with SCD
  • Lack of Resources and Skilled Clinical Laboratory Workforce Shortages

Porter's Five Forces: A Strategic Tool for Navigating the Sickle Cell Anemia Testing & Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sickle Cell Anemia Testing & Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sickle Cell Anemia Testing & Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sickle Cell Anemia Testing & Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sickle Cell Anemia Testing & Screening Market

A detailed market share analysis in the Sickle Cell Anemia Testing & Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sickle Cell Anemia Testing & Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sickle Cell Anemia Testing & Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Sickle Cell Anemia Testing & Screening Market, highlighting leading vendors and their innovative profiles. These include Biomedomics Inc., HiMedia Laboratories, Pfizer Inc., Silver Lake Research Corporation, Thermo Fisher Scientific Inc., Vertex Pharmaceuticals Incorporated, Edvotek Inc., Atlas Medical GmbH, Hemex Health, Quest Diagnostics Incorporated, CRISPR Therapeutics AG, Anamol Laboratories Pvt. Ltd., Ulta Lab Tests, LLC, Bio-Rad Laboratories, Inc., Bio Lab Diagnostics (I) Private Limited, PerkinElmer, Inc., Bluebird bio, Inc., Streck, Inc., Maternova Inc., Laboratory Corporation of America Holdings, Calibre Scientific, Inc., PicnicHealth, and Agios Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Sickle Cell Anemia Testing & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), and Point-of-Care Tests. The Hemoglobin Electrophoresis is further studied across Isoelectric focusing. The Point-of-Care Tests is further studied across Lateral Flow Immunoassay and Paper Based Rapid Diagnostics.
• Based on Age Group, market is studied across Adult Screening, Newborn Screening, and Years 1 to 25.
• Based on Sector, market is studied across Corporate Labs, Government Labs, Private Labs, and Public-Private-Partnerships.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of Sickle Cell Disease Worldwide
    • 5.1.1.2. Ongoing Government Initiatives to Support the Diagnosis
    • 5.1.1.3. Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
  • 5.1.2. Restraints
    • 5.1.2.1. Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
  • 5.1.3. Opportunities
    • 5.1.3.1. Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
    • 5.1.3.2. Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Clinical Heterogeneity and Complications Associated with SCD
    • 5.1.4.2. Lack of Resources and Skilled Clinical Laboratory Workforce Shortages
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Ongoing advancements hemoglobin electrophoresis for initial screening particularly in newborns
  • 5.2.2. Sector: Corporate labs are at the forefront of innovation and technology to provide comprehensive services
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Sickle Cell Anemia Testing & Screening Market, by Technology

• 6.1. Introduction
• 6.2. Hemoglobin Electrophoresis
  • 6.2.1. Isoelectric focusing
• 6.3. High-performance Liquid Chromatography (HPLC)
• 6.4. Point-of-Care Tests
  • 6.4.1. Lateral Flow Immunoassay
  • 6.4.2. Paper Based Rapid Diagnostics

7. Sickle Cell Anemia Testing & Screening Market, by Age Group

• 7.1. Introduction
• 7.2. Adult Screening
• 7.3. Newborn Screening
• 7.4. Years 1 to 25

8. Sickle Cell Anemia Testing & Screening Market, by Sector

• 8.1. Introduction
• 8.2. Corporate Labs
• 8.3. Government Labs
• 8.4. Private Labs
• 8.5. Public-Private-Partnerships

9. Americas Sickle Cell Anemia Testing & Screening Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Sickle Cell Anemia Testing & Screening Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Sickle Cell Anemia Testing & Screening Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. USD 3 million awarded to study repurposing of blood pressure drug for SCD
  • 12.3.2. Mylab introduces indigenous Point-of-care, Rapid Sickle Cell Anemia Test
  • 12.3.3. Lord's Mark Industries, IIT-Bombay partner to advance sickle cell testing in India

Companies Mentioned

• 1. Biomedomics Inc.
• 2. HiMedia Laboratories
• 3. Pfizer Inc.
• 4. Silver Lake Research Corporation
• 5. Thermo Fisher Scientific Inc.
• 6. Vertex Pharmaceuticals Incorporated
• 7. Edvotek Inc.
• 8. Atlas Medical GmbH
• 9. Hemex Health
• 10. Quest Diagnostics Incorporated
• 11. CRISPR Therapeutics AG
• 12. Anamol Laboratories Pvt. Ltd.
• 13. Ulta Lab Tests, LLC
• 14. Bio-Rad Laboratories, Inc.
• 15. Bio Lab Diagnostics (I) Private Limited
• 16. PerkinElmer, Inc.
• 17. Bluebird bio, Inc.
• 18. Streck, Inc.
• 19. Maternova Inc.
• 20. Laboratory Corporation of America Holdings
• 21. Calibre Scientific, Inc.
• 22. PicnicHealth
• 23. Agios Pharmaceuticals, Inc.